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Abstract
Background: To ascertain whether the associations between obesity, inflammation, and insulin resistance
established in human adult studies are found among adolescents.
Methods: We contrasted 36 obese and 24 lean youth on fasting glucose, insulin levels, lipid profile, hemoglobin
A1C, markers of hepatic function, white blood cell count, C-reactive protein (CRP) and fibrinogen levels. The
cytokines IL-6, TNF-α, IFN-γ, IL-10 and IL-4 and the adipokines leptin, resistin, and adiponectin were also compared
between the two groups. The fasting glucose and insulin values were used to estimate the degree of insulin
resistance with the homeostatic model assessment of insulin resistance (HOMA-IR). T-tests and correlations were run
to examine group differences and associations between groups. In addition, regression analyses were used to
ascertain whether the markers of inflammation were predictive of the degree of insulin resistance.
Results: Although obese adolescents had clear evidence of insulin resistance, only CRP, fibrinogen and leptin were
elevated; there were no group differences in pro- or anti-inflammatory cytokines nor adiponectin and resistin.
Anthropometric measures of obesity and level of insulin resistance were highly correlated to the acute phase
reactants CRP and fibrinogen; however, the degree of insulin resistance was not predicted by the pro- or
anti-inflammatory cytokine markers. Obese adolescents had higher white blood cell counts. In addition they had
higher circulating alanine aminotransferase concentrations and lower circulating albumin and total protein than
lean adolescents, possibly as a result of hepatocyte damage from fatty liver.
Conclusion: Unlike rodent or adult studies, we found that wide-spread systemic inflammation is not necessarily
associated with insulin resistance among adolescents. This finding does not support the current paradigm that the
associations between obesity and insulin resistance are, to a significant degree, mediated by low grade systemic
inflammation. These data support the need for further adolescent studies to explore these associations.
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Introduction
Obesity is considered a low-grade chronic inflammatory
disease that may contribute to the development of insu-
lin resistance [1]. Obese adults and adolescents are at
higher risk for developing type 2 diabetes, cardiovascular
disease, non-alcoholic fatty liver disease (NAFLD) and
several forms of cancer [2-5]. Previous research suggests
that mediators of low grade chronic inflammation, such
as cytokines and acute phase reactants, contribute to the
development of these co-morbid conditions [6,7]. In the
adult human, the very high co-occurrence of obesity,
inflammation and insulin resistance bolsters the hypoth-
esis that obesity-associated inflammation may lead to
insulin resistance [8,9]. However, there is not complete
consensus on this matter [10]. It is important to improve
our understanding of the pathophysiology involved in
the progression from obesity to insulin resistance,
particularly in youth where obesity and insulin resistance
may still be dissociated.
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Over the last two decades, our view of adipose tissue
was transformed from that of an “inert” storage tissue
to an endocrine organ that secretes a number of pro-
teins, such as adiponectin, resistin, and leptin [11-14].
Adiponectin is anti-inflammatory, while resistin is pro-
inflammatory, and their imbalance can result in low
grade inflammation [15,16]. Leptin, another adipokine
that increases with adiposity, is an important satiety
signal, and obese individuals may become resistant to
leptin resulting in greater production and secretion of
this protein [8,17]. Both leptin and resistin are corre-
lated with insulin resistance and are considered key
mediators linking insulin resistance with hepatic stea-
tosis [18].
As adipocytes store larger lipid droplets and increase
in size, the physical stress on the blood vessels that
supply them increases leading to a compromised endo-
thelial lining [19]. This facilitates macrophage infiltra-
tion, which in turn increases cytokine production [6].
Another possible cause of increased cytokine expression
is damage to specific organs, for example the liver.
Hepatic steatosis is an imbalance in triglyceride acquisi-
tion and removal, resulting in the storage of excess tri-
glycerides by hepatocytes. This can result in the
increased production of inflammatory cytokines, such
as tumor necrosis factor (TNF)-α, by resident macro-
phages [3]. Acute phase reactants produced in the liver,
such as C-reactive protein (CRP) and fibrinogen, are
also elevated in obese adults and are implicated in the
development of cardiovascular, kidney disease and dia-
betes [20-22].
The pathophysiology of inflammation among obese
children and adolescents is less well-developed, and no
clear consensus exists in the pediatric literature [23,24].
Most pediatric studies show consistent increases in
CRP, but not increases in interleukin (IL)-6 and TNFα
nor decreases in IL-10 or IL-4. These are important
issues to consider given the large variability in the de-
gree of insulin resistance among obese adolescents
[25,26].
We hypothesized that the associations between key
biomarkers of obesity and insulin resistance in adoles-
cents may exist at an organ system level but perhaps not
systemically, thus resulting in the inconsistent results
reported in this age group. To test this hypothesis we
assessed markers of the immune system, liver markers,
pro- and anti-inflammatory cytokines, adipokines, and
acute phase reactants in a group of lean and obese ado-
lescents. Based on clear fasting hyperinsulinemia among
our obese adolescents, suggesting significant levels of in-
sulin resistance, we also ascertained whether obesity/in-
sulin resistance is associated with systemic changes in




Sixty adolescents, 24 lean and 36 obese, matched on age,
gender, school grade, ethnicity, and socioeconomic sta-
tus (Table 1) were studied. The subjects were consecu-
tive cases evaluated as part of an NIH-sponsored study
at the Brain, Obesity, and Diabetes Laboratory, Depart-
ment of Psychiatry, New York University School of
Medicine. The study was approved by the local IRB. All
of the participants (and, if they were under 18 years of
age, their parent) signed informed consent and received
compensation for their time and inconvenience. Partici-
pants were screened to rule out exclusionary preexisting
medical and psychiatric conditions. Hypertension, dysli-
pidemia, and insulin resistance were allowed. None of
the study subjects were receiving any psychotropic medi-
cations. The original participant pool contained 117 ado-
lescents. Of the 117 adolescents, 19 were excluded
because they had either CRP > 10 mg/L, which may be
indicative of an acute inflammation or infection [27], or
had missing CRP values. Additionally, 18 possible parti-
cipants were excluded because they were receiving anti-
Table 1 Group differences in demographic and biological
parameters
Lean Obese p-value
Gender (% female) 58.3 55.6 0.832
Race/Ethnicity χ2 = 1.02
White (%) 33.3 38.9
Hispanic (%) 25.0 27.8
African American (%) 25.0 25.0
Asian (%) 16.7 8.3
Age (yrs) 17.2 ± 0.4 17.5 ± 0.3 0.396
Grade 11.2 ± 0.4 11.4 ± 0.2 0.708
BMI (kg/m2) 21.5 ± 0.5 37.4 ± 1.2 0.000**
Waist Circumference (cm) 76.8 ± 1.2 112.2 ± 2.8 0.000**
Waist:Height 0.45 ± 0.01 0.66 ± 0.01 0.000**
Waist:Hip 0.85 ± 0.01 0.94 ± 0.01 0.000**
Glucose (mg/dL) 73.5 ± 1.4 77.3 ± 1.5 0.083
Insulin (IU/mL) 7.4 ± 0.6 18.4 ± 2.0 0.000**
HOMA-IR 1.3 ± 0.1 3.5 ± 0.4 0.000**
Hemoglobin A1C (%) 5.1 ± 0.1 5.4 ± 0.1 0.000**
Total cholesterol (mg/dL) 160.5 ± 5.9 164.1 ± 5.3 0.662
LDL (mg/dL) 91.5 ± 5.1 102.6 ± 4.7 0.125
HDL (mg/dL) 55.0 ± 2.5 43.7 ± 1.5 0.000**
Triglycerides (mg/dL) 70.6 ± 5.6 89.4 ± 7.2 0.064
Systolic BP (mmHg) 101.3 ± 1.9 115.3 ± 2.0 0.000**
Diastolic BP (mmHg) 63.2 ± 1.7 68.0 ± 1.5 0.036*
*Denotes a p-value of >0.05; **denotes a p-value of ≤0.010.
Body mass index (BMI); homeostatic model assessment of insulin resistance
(HOMA-IR); low density lipoprotein (LDL); high density lipoprotein (HDL);
blood pressure (BP).
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inflammatory or β-agonist medications and 10 had a his-
tory of inflammatory illnesses (e.g., asthma). Lastly, 10
participants did not have stored plasma available for
measurement of cytokine and adipokine concentrations.
The 57 excluded and 60 evaluated did not differ on age,
race, gender, or BMI.
Blood collection
Following a 10–12 hour fast, blood was collected from
all participants at 09:00 hours in a standardized fashion.
Standard blood tests, such as CBC with differential,
comprehensive metabolic profile including glucose and
insulin levels, lipid profile, hemoglobin A1C, CRP, fi-
brinogen levels, white blood cell (WBC) count and mar-
kers of liver function were performed at the NYU
Medical Center Clinical Laboratories. In addition to the
blood samples used for the clinical labs, samples were
collected in EDTA tubes, placed immediately on ice,
spun at 4°C at 1,700 RPM for 10 minutes, and the
plasma was stored at −80°C for future cytokine and adi-
pokine assays, which were performed at the NYU Clin-
ical Translational Science Institute core laboratory.
Estimation of insulin resistance
As an estimate of insulin resistance, fasting glucose
and insulin levels were used to compute the homeo-
static model assessment of insulin resistance (HOMA-
IR). HOMA-IR has been validated against the
hyperinsulinemic-euglycemic clamp [28]. HOMA-IR
values above 3.16 are considered indicative of insulin
resistance in adolescence, whereas those under 1.99
suggest an absence of insulin resistance [29].
Circulating cytokine and adipokine measurements
Plasma samples were thawed on ice. ELISAs using
Multiplex plates (Millipore, Billerica, MA) were per-
formed. The plates were pre-coated with antibodies to
the proteins of interest and plasma samples were loaded
onto the plates per the manufacturer’s instructions.
Plates were read on a Luminex plate reader (Austin,
TX). Protein concentrations were determined by com-
paring the unknown sample concentrations to those of
standard curves.
Statistical analysis
Data were analyzed using SPSS for Windows version
19.0 (SPSS, Inc., Chicago, IL). The Shapiro-Wilk test was
used to test data normality. Independent t-tests were
used to investigate group differences in demographics,
metabolic parameters including HOMA-IR and fasting
insulin levels, liver parameters, white cell counts, adipo-
kines, cytokines and acute phase proteins. Exploratory
analyses were conducted using the Pearson’s or Spear-
man’s correlation to investigate whether markers of
adiposity, insulin resistance, liver injury and immune
responses were associated with circulating CRP and fi-
brinogen levels. We used linear and hierarchical regres-
sions to account for potential confounders, such as
gender, ethnicity and blood pressure. To formally test
whether levels of the inflammatory markers accounted
for the degree of insulin resistance, we used linear
regressions with HOMA-IR (or fasting insulin level) as
the dependent variable, and after accounting for possible
confounds (age and gender), we evaluated the contribu-
tion of the different cytokines to the variance in these
dependent variables.
Results
Demographic and endocrine data
The participants were, on average, approximately
17 years of age with an 11th grade education (Table 1).
As expected the obese group had significantly higher
HOMA-IR, fasting insulin, and hemoglobin A1C values
compared to the lean group. Although all subjects had
fasting glucose levels in the normal range, the obese
group tended towards higher fasting glucose levels
(Table 1). The average BMI of the lean group was
21.5 kg/m2 and the average BMI for the obese group
was 37.4 kg/m2. Not surprisingly, the obese group had
larger waist circumference and larger waist-to-height
and waist-to-hip ratios than the lean group. Lastly, the
obese group also had lower HDL concentrations and
higher blood pressure than the lean group (Table 1). Al-
though the differences in triglyceride concentrations did
not reach statistical significance, there was a statistical
trend for increased triglyceride concentration in the
obese group (Table 1).
The liver panel revealed no group differences in aspar-
tate aminotransferase (AST), alkaline phosphatase, or
bilirubin. However, as indicated on Table 2, obese ado-
lescents had higher circulating concentrations of alanine
aminotransferase (ALT). Both circulating total protein
and albumin were higher in the lean group and the
Table 2 Hepatic markers and white blood cell
(WBC) count
Lean Obese p-value
ALT (U/L) 23.9 ± 1.2 42.3 ± 5.5 0.002**
AST (U/L) 29.3 ± 2.5 31.0 ± 2.4 0.647
Alkaline Phosphatase (mg/dL) 91.4 ± 6.1 92.8 ± 4.7 0.855
Total Bilirubin (U/L) 0.5 ± 0.1 0.4 ± 0.0 0.416
Total Protein (gm/dL) 7.8 ± 0.5 7.5 ± 0.4 0.010**
Albumin (mg/dL) 4.7 ± 0.3 4.3 ± 0.3 0.000**
WBC (103/mL) 5.5 ± 0.8 6.8 ± 1.8 0.000**
**denotes a p-value of ≤0.010.
Alanine aminotrasferase (ALT); aspartate aminotransferase (AST); white blood
cell (WBC).
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obese group had a higher WBC value than the lean
group (Table 2).
Differences in cytokine, adipokine, and acute phase
reactant concentrations between lean and
obese adolescents
There were no group differences in the concentration of
either the pro-inflammatory cytokines IL-6, TNFα, and
IFN-γ (Table 3) or the anti-inflammatory cytokines IL-
10 and IL-4 (Table 3). There were also no group differ-
ences in adiponectin and resistin. However, relative to
lean adolescents, obese adolescents had nearly a 4-fold
higher leptin concentration (Table 3). Obese adolescents
also had a significant elevation (nearly 7-fold higher) in
circulating CRP levels compared to the lean adolescents
(Table 3). Please note that all adolescents with CRP
levels greater than 10 mg/dl were excluded from the
sample [27]. All of the lean adolescents had CRP levels
under 1 mg/dl. The obese group also had significantly
higher fibrinogen levels (about a 14 % elevation) com-
pared to the lean group (Table 3).
There were strong positive associations between CRP
and fibrinogen and BMI, waist circumference, waist-to-
height ratio and HOMA-IR values (Table 4). CRP con-
centrations were positively associated with ALT and
WBC and negatively associated with total protein and al-
bumin (Table 5). Fibrinogen was positively associated
with ALT and WBC (Table 5).
None of the pro- or anti-inflammatory cytokines levels
were predictive of fasting insulin levels or HOMA-IR
scores for all subjects combined or either group alone.
Discussion
We found clear elevations in the acute phase reactants
CRP and fibrinogen, as well as in insulin resistance
among obese adolescents. However, we found no differ-
ences in pro- or anti-inflammatory cytokine expression
between obese and lean adolescents, nor did we find any
association between cytokine levels and our measures of
insulin resistance. This could be partly an issue of detec-
tion, since cytokine concentrations are generally orders
of magnitude lower than what is seen with acute phase
reactants. However, given that we had detectable levels
of all cytokines, just no differences between lean and
obese, and that this is in agreement with other studies in
youth, our results suggest that the association between
cytokines and insulin resistance may differ in youth and
adults. Importantly, we had a clear difference in the level
of insulin resistance between lean and obese groups, as
well as clear associations between insulin resistance and
measures of obesity and of acute phase reactants.
While circulating pro-inflammatory cytokines are, in the
majority of studies, elevated in adult obesity [8-10], the lit-
erature on inflammatory cytokines in adolescents is quite
mixed [23,24]. Tam et al. [30] suggests that ethnicity and
gender may contribute to differences in cytokine expres-
sion; however, in this study neither gender nor ethnicity
accounted for the lack of cytokine differences by BMI
group. Our negative results may be in part due to low stat-
istical power from our relatively small sample size. How-
ever, another possible explanation for the differences
between adult and adolescent studies is that adolescents
may have been obese for a relatively short time. Increases
in inflammatory cytokine concentrations are, in part, the
result of macrophage infiltration into the adipose tissue
[6,31,32], and it is possible that more time is required for
this infiltration to occur. The current data is consistent
with others showing that increases in CRP and fibrinogen
precede increases in cytokine expression in the circulation
[30]. Furthermore, unlike cytokines which are primarily
produced by activated macrophages, CRP and fibrinogen
expression can be elevated through other mechanisms
such as activation of the complement system, a compo-
nent of the innate immune response [33]. We found that
the obese group had higher WBC count, suggesting acti-
vation of the innate immune response.
Although differences in circulating levels of cytokines
were not observed, it is possible that there was increased
cytokine expression in specific organs like the liver.
Obesity and elevated fasting glucose levels are risk fac-
tors for the development of NAFLD [18]. Lipolysis of
adipose tissue, de novo hepatic lipogenesis, and diet are
the main sources of hepatic triglycerides [3]. The accu-
mulation of triglycerides in the cytosol of hepatocytes
leads to cell damage and increased production of inflam-
matory cytokines [18]. In this study, obese adolescents
had higher circulating levels of ALT, an enzyme that is
released into the circulation specifically by injured hepa-
tocytes [34]. The elevated ALT, higher triglycerides, and
Table 3 Circulating cytokine, adipokine and acute phase
reactant concentrations
Lean Obese p-value
TNFα (pg/ml) 3.4 ± 2.1 3.5 ± 2.0 0.900
IL-6 (pg/ml) 8.1 ± 6.8 9.3 ± 8.4 0.588
IFN-γ (pg/ml) 14.1 ± 12.8 11.4 ± 8.0 0.321
IL-4 (pg/ml) 77.4 ± 54.8 79.5 ± 49.1 0.877
IL-10 (pg/ml) 22.5 ± 21.4 26.3 ± 46.3 0.715
Leptin (ng/ml) 10.9 ± 11.1 38.1 ± 25.6 0.000**
Adiponectin (ng/ml) 766.8 ± 165.9 112.0 ± 233.1 0.652
Resistin (pg/ml) 102.8 ± 65.3 119.2 ± 117.3 0.538
Acute phase reactants
CRP (mg/L) 0.5 ± 0.4 3.3 ± 2.2 0.000**
Fibrinogen (mg/L) 278.2 ± 33.3 327.9 ± 54.4 0.000**
**denotes a p-value of ≤0.010.
Tumor necrosis factor (TNF); interferon (IFN); interleukin (IL); C-reactive
protein (CRP).
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greater central obesity present in our obese group may
suggest the presence of hepatic inflammation, which in
turn may contribute to the elevated acute phase reactants
seen among them. Additionally, our obese adolescents
had lower protein and albumin in their circulation, which
may also suggest hepatic injury or compromise [35].
In adults, the current paradigm is that obesity-
mediated insulin resistance contributes to impaired
endothelial cell function. There are several mechanisms
that may lead to compromised endothelium. One pos-
sible cause of these impairments may be the accumula-
tion of advanced glycation end-products, a byproduct of
glycation and oxidative stress [36]. These impairments
in endothelial function allow macrophages to extravasate
from blood vessels into adipose tissue [8,37]. It is these
infiltrating macrophages, rather than the stromovascular
cells or the adipocytes themselves, that produce inflam-
matory cytokines [37]. This infiltration changes the en-
vironment of the adipose tissue making it more pro-
inflammatory [38]. Furthermore, insulin resistance itself
leads to activation of pro-inflammatory M1 macrophages
in the adipose tissue leading to increased cytokine and
chemokine production and recruitment of foreign
macrophages into the tissue [18]. Longitudinal studies of
youth are needed to elucidate if and how the adipose tis-
sue environment changes in response to obesity.
Rodent studies suggest that obesity-associated low
grade chronic inflammation is critical for the develop-
ment of insulin resistance [39,40]. The c-Jun N-terminal
kinase pathway is central in the cascade leading from in-
flammation to insulin resistance. These relationships are
not well understood, and most human studies in adults
are cross-sectional and only establish a co-occurrence of
inflammation and insulin resistance, but cannot inform
which occurs first [8,9]. The few existent prospective
human studies use non-naturalistic experimental diet
paradigms that cause rapid weight gain, but also hyper-
glycemia, and are therefore not optimal to elucidate the
physiological mechanism behind gradual weight gain
leading to insulin resistance [32]. In contrast to adult
studies, where obesity is most frequently associated with
insulin resistance, adolescents can be obese without hav-
ing overt insulin resistance. For this reason, adolescents
provide a more straightforward opportunity to investi-
gate the causal relationship between inflammation and
insulin resistance in the human. Our data clearly sug-
gests that among obese adolescents insulin resistance
may precede the elevation of systemic cytokines and
some adipokines.
The adipokines adiponectin and resistin were not dif-
ferent across our lean and obese adolescent groups,
whereas leptin was significantly higher in the obese
group. Unlike adiponectin and resistin, leptin is a satiety
signal [41]. Leptin expression can be increased by gastric
hormones like ghrelin [42] and as a compensatory
mechanism for the leptin resistance that is frequently
observed in obesity [43]. Also, unlike adiponectin and
resistin, which are only produced by adipocytes, leptin is
also produced by gastric epithelium cells and glands in
the gastric fundus [44]. Lastly, adiponectin and resistin
are more sensitive to changes in inflammatory homeo-
stasis. Increases in inflammation can decrease adiponec-
tin and increase resistin; however, leptin expression is
not as sensitive to these biological changes [8]. These
relationships are clearly captured in our data, where we
showed elevations in the acute phase reactants and lep-
tin but not in inflammatory cytokines nor adiponectin
and resistin.
Our study has some notable limitations. We do not
know how long our subjects were obese, but given their
Table 4 Associations between acute phase reactants and indicators of obesity and insulin resistance
CRP Correlation Coefficient p-value Fibrinogen Correlation Coefficient p-value
BMI 0.748 0.000** BMI 0.490 0.000**
Waist Circumference 0.785 0.000** Waist Circumference 0.532 0.000**
Waist:Height 0.774 0.000** Waist:Height 0.550 0.000**
HOMA-IR 0.520 0.000** HOMA-IR 0.475 0.001**
**denotes a p-value of ≤0.010.
Body mass index (BMI); homeostatic model assessment of insulin resistance (HOMA-IR).
Table 5 Associations between acute phase reactants and hepatic markers and white blood cell (WBC) count
Correlation Coefficient with CRP p-value Correlation Coefficient with Fibrinogen p-value
ALT 0.535 0.000** 0.464 0.001**
Total Protein −0.264 0.042* −0.066 0.654
Albumin −0.377 0.003** −0.250 0.087
WBC 0.447 0.000** 0.461 0.001**
*denotes a p-value of <0.05; **denotes a p-value of ≤0.010.
Alanine aminotrasferase (ALT); white blood cell (WBC).
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young age, variability is likely somewhat limited. Add-
itionally, as a measure of insulin resistance we used
HOMA-IR, which although highly correlated to the
results of dynamic assessments of insulin function such
as the hyperinsulinemic-euglycemic clamp, remains a
single point static measure. Future studies should utilize
dynamic assessments of insulin function. Our study is
strengthened by the examination of several pro- and
anti- inflammatory cytokines and adipokines, using well-
established methods. The cytokines and adipokines mea-
sured in this study are strongly associated with obesity
and insulin resistance in adults [9]. All of the samples
we assayed for cytokines and adipokines were measured
simultaneously, which limited variability inherent in dif-
ferent kits. This also obviated the need for repeated
freezing and thawing of the samples. An additional
strength of this study was our naturalistic study design.
Unlike other human studies, our obese adolescents with
insulin resistance were carefully matched to lean sub-
jects and both groups had normal fasting glucose levels,
which allowed us to ascertain these associations during
the natural development of obesity and insulin resist-
ance, independent of rapid weight gain and hypergly-
cemia from experimental diet interventions [32].
In the future more studies are needed to elucidate the
pathogenesis leading to insulin resistance. Follow up
studies should include measures of ceremide concentra-
tion [45], TNFα receptor [46] and markers of polycystic
ovary syndrome. It is still unknown how long excess adi-
posity needs to be present before macrophage infiltra-
tion begins. Furthermore, if contrary to the widely held
belief, a systemic increase in cytokine concentration does
not necessarily precede insulin resistance, more work
needs to be done in the adolescent human to identify
other possible mechanisms that contribute to insulin
resistance.
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